Immunomodulatory Effects of NB-UVB and Steroids in Vitiligo: A Study on CXCL11 and TEMRA Biomarkers
NCT ID: NCT06946069
Last Updated: 2025-04-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
40 participants
INTERVENTIONAL
2025-09-01
2026-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Contribution of Skin Color in Stabilization of Active Cases of Vitiligo by Narrow Band UVB
NCT04030988
Effectiveness of Narrow-band Ultraviolet B Combined With Topical Tacrolimus 0.03% in Treatment of Patients With Vitiligo
NCT03199664
Narrowband UVB Treatment in Patients With Vitiligo
NCT00398723
Randomized, Split-body, Single-blinded Clinical Trial of NB-UVB Treatment for Vitiligo
NCT02506101
Effect of NB-UVB on the Tissue Level of IL 15 and IL-15Rα in Active Non Segmental Vitiligo Cases.
NCT05316987
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Randomized controlled trial (RCT) with two parallel arms.
Duration: Six months (including baseline and follow-up assessments).
Setting: Outpatient dermatology clinic at Assiut University Hospital, Egypt.
Objectives:
Compare the immunomodulatory effects of NB-UVB alone vs. NB-UVB + OMP steroids in vitiligo patients.
Assess CXCL11 and TEMRA levels as potential biomarkers for disease activity and treatment response.
Evaluate clinical repigmentation using Vitiligo Extent Score (VES/VESplus).
Methodology:
40 patients with stable non-segmental vitiligo will be enrolled.
20 patients will undergo serum analysis for CXCL11 and TEMRA via ELISA.
Treatment arms:
NB-UVB monotherapy (twice weekly).
NB-UVB + OMP steroids (dexamethasone 2.5-3 mg/week).
Follow-up: Clinical and immunological assessments at baseline and 6 months.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
Participants are randomly assigned (1:1 ratio) to one of two treatment arms:
NB-UVB monotherapy (control group).
NB-UVB + oral mini-pulse (OMP) steroids (intervention group).
Both groups receive simultaneous but distinct interventions for direct comparison.
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1 (NB-UVB Monotherapy)
Standard phototherapy without additional systemic treatment.
NB-UVB twice weekly
Standard phototherapy without additional systemic treatment.
Group 2 (NB-UVB + OMP Steroids)
Combination therapy of NB-UVB + OMP Steroids to enhance immunosuppression and repigmentation.
NB-UVB + dexamethasone (2.5-3 mg/week)
Combination therapy to enhance immunosuppression and repigmentation.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
NB-UVB twice weekly
Standard phototherapy without additional systemic treatment.
NB-UVB + dexamethasone (2.5-3 mg/week)
Combination therapy to enhance immunosuppression and repigmentation.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Fitzpatrick skin types III-V (common in the Egyptian population).
No recent systemic therapy for vitiligo (within the last 3 months).
Exclusion Criteria
Pregnancy or breastfeeding.
Active infections, malignancies, or immunosuppressive conditions.
History of hypertrophic scarring or melanoma.
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assiut University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
ALZAHRA MOAHMED MOHAMED ABDELHAFEZ
resident at the dermatology Surgery department
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Effects of NB-UVB and Steroids
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.